![Matthew Riddle MD](https://res.cloudinary.com/els-assets/image/upload/c_fill_pad,f_auto,g_auto,h_150,q_auto,w_120/v1/practice-update/remote-media/contentimage/3214.jpg)
Matthew Riddle MD
Professor of Medicine, Division of Endocrinology, Diabetes &, Clinical Nutrition, Oregon Health & Science University, Portland, OregonDr. Riddle attended Yale University (BA 1960, magna cum laude) and Harvard Medical School (MD 1964). He did internship and residency in internal medicine at Rush-Presbyterian-St.Luke’s Medical Center in Chicago, and completed two fellowships in Endocrinology and Metabolism, one at Rush Presbyterian-St.Luke’s with Dr. Theodore Schwartz (1969-71), the other at the University of Washington in Seattle with Dr. Robert Williams (1971-73). Since 1973 he has been at Oregon Health & Science University, where he is Professor of Medicine in the Division of Endocrinology, Diabetes, & Clinical Nutrition. His interests include the physiology of type 2 diabetes, basal insulin therapy, newer therapeutic agents, combination therapy, cardiovascular outcomes of diabetes, and the organization of care for diabetes. He has more than 210 completed publications, is an Associate Editor of Diabetes Care, and has served on Editorial Boards of Diabetes Technology & Therapeutics and the Journal of Clinical Endocrinology & Metabolism. Among other activities in clinical research he has leadership responsibilities in various large international trials, including ACCORD/ACCORDION, ORIGIN/ORIGINALE, ELIXA, EXSCEL, REWIND, and DCCT/EDIC, all of which are testing the effects of treatments on cardiovascular and other medical outcomes in diabetes. The American Diabetes Association gave him their Outstanding Physician-Clinician Award for year 2005.
Disclosures
Dr. Riddle reports research support through his institution and/or or honoraria for consulting from Astra-Zeneca, Eli Lilly, Novo-Nordisk, and Sanofi, manufacturers of insulins and GLP-1 agonists. These dualities have been reviewed and managed by Oregon Health & Science University.